GenoType MTBDRsl for detection of second-line drugs and ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates at a high-throughput laboratory
Diagn Microbiol Infect Dis
;
105(2): 1-9, 2022.
Article
in English
| LILACS, CONASS, ColecionaSUS, SES-SP, SESSP-IALPROD, SES-SP
| ID: biblio-1424922
ABSTRACT
We assessed the performance of MTBDRsl for detection of resistance to fluoroquinolones, aminoglycosides/cyclic peptides, and ethambutol compared to BACTEC MGIT 960 by subjecting simultaneously to both tests 385 phenotypically multidrug-resistant-Mycobacterium tuberculosis isolates from Sao Paulo, Brazil. Discordances were resolved by Sanger sequencing. MTBDRsl correctly detected 99.7% of the multidrug-resistant isolates, 87.8% of the pre-XDR, and 73.9% of the XDR. The assay showed sensitivity of 86.4%, 100%, 85.2% and 76.4% for fluoroquinolones, amikacin/kanamycin, capreomycin and ethambutol, respectively. Specificity was 100% for fluoroquinolones and aminoglycosides/cyclic peptides, and 93.6% for ethambutol. Most fluoroquinolone-discordances were due to mutations in genome regions not targeted by the MTBDRsl v. 1.0 gyrA_H70R and gyrB_R446C, D461N, D449V, and N488D. Capreomycin-resistant isolates with wild-type rrs results on MTBDRsl presented tlyA mutations. MTBDRsl presented good performance for detecting resistance to second-line drugs and ethambutol in clinical isolates. In our setting, multidrug-resistant. isolates presented mutations not targeted by the molecular assay.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Amikacin
/
Sensitivity and Specificity
/
Genome
/
Diagnosis
/
Mycobacterium tuberculosis
Type of study:
Diagnostic study
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2022
Type:
Article
Institution/Affiliation country:
Núcleo de Tuberculose e Micobacterioses/BR
Similar
MEDLINE
...
LILACS
LIS